Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 28, 2024 at 09:05 pm
Share
Crinetics Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 60.1 million compared to USD 44.99 million a year ago. Basic loss per share from continuing operations was USD 0.9 compared to USD 0.84 a year ago.
For the full year, sales was USD 4.01 million compared to USD 4.74 million a year ago. Net loss was USD 214.53 million compared to USD 163.92 million a year ago. Basic loss per share from continuing operations was USD 3.69 compared to USD 3.15 a year ago.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.